Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas

Table 2 Relationship between clinical characteristics and immune markers

	Low CD8 n (%)	High CD8 n (%)	P-value	Low FOXP3 n (%)	High FOXP3 n (%)	P-value	Low PD-1 n (%)		High PD-1 n (%)	P-value	Low PD-L1 n (%)	High PD-L1 n (%)	P-value
Age (yr)
< 60	7	8	0.835	11	4	0.019	9		6	0.284	7	8	0.666
≥ 60	14	14		10	18		12		16		15	13
Gender
Male	17	18	0.942	14	21	0.015		16	19	0.391	19	16	0.391
Female	4	4		7	1			5	3		3	5
Tumor location
Cardia	9	12	0.492	11	10	0.018		10	11	0.999	11	10	0.489
Corpus	7	3		1	9			5	5		5	5
Antrum	4	6		7	3			5	5		4	6
Residual stomach anastomosis	1	1		2	0			1	1		2	0
Tumor size
≤ 5 cm	12	8	0.172	11	9	0.451		11	9	0.451	10	10	0.887
> 5 cm	9	14		10	13			10	13		12	11
T classification
T1/2	3	1	0.272	2	2	0.961		2	2	0.961	1	3	0.272
T3/4	18	21		19	20			19	20		21	18
Lymph node metastasis
≤ 7	5	7	0.558	3	9	0.052		5	7	0.558	6	6	0.924
> 7	16	15		18	13			16	15		16	15
Liver metastasis
Absent	17	20	0.346	18	19	0.951		16	21	0.068	19	18	0.951
Present	4	2		3	3			5	1		3	3
CD8
High
Low
FOXP3
Low	9	12	0.443
Hight	12	10
PD-1
Low	13	8	0.094	12	9	0.287
High	8	14		9	13
PD-L1
Low	9	13	0.287	12	10	0.443		15	7	0.009
High	12	9		9	12			6	15

PD-L1: Programmed death ligand 1; PD-1: Programmed death 1.